Peptide D
Latest Information Update: 17 Jul 2001
At a glance
- Originator Imperial Cancer Research Technology
- Class Antineoplastics
- Mechanism of Action Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jul 2001 Discontinued-Preclinical for Cancer in Australia (Unknown route)
- 17 Jul 2001 Discontinued-Preclinical for Cancer in Denmark (Unknown route)
- 17 Jul 2001 Discontinued-Preclinical for Cancer in Sweden (Unknown route)